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Abstract. Expression of osteopontin (OPN) is increased in 
prostate cancer cells. The possibility of utilising the increased 
OPN as a target to suppress the tumourigenicity was investigated 
in this study. Small interference RNAs against OPN were 
transfected into highly malignant DU145 prostate cancer cells, 
which express high level of OPN prior to the transfections, 
to establish OPN-suppressed clones. Compared with the 
control transfectants generated by scrambled RNA, suppressed 
expression of OPN significantly inhibited cell invasiveness 
and anchorage-independent growth. Similar results were 
obtained from in vivo experiments. OPN-suppressed transfectants 
produced significant reductions in average sizes of subcutaneous 
tumours after inoculation into nude mice. When the levels 
of OPN measured in transfectants before injection were 
related to tumour sizes, the reduction in tumour sizes was not 
propotionally related to the inhibition in OPN-levels. However, 
when the levels of OPN were analysed in the tumour tissues, 
it was found that the reduced OPN expression levels were 
significantly associated with the reducing tumour sizes. These 
results showed that changes in OPN levels had occurred after 
the transfectants were inoculated in mice. This study suggested 
while OPN can be an effective target for therapeutic suppression 
of prostate cancer, more effective way than RNAi is needed to 
inhibit OPN expression.
Introduction
The pathogenesis of prostate cancer involves complicated 
molecular biology events. Like other malignant diseases, over-
expression of cancer-promoting genes is one of the most 
important causes for the development and spread of prostate 
cancer cells. Identification of these cancer-promoting genes 
and investigation of their potential as targets for therapeutic 
intervention is of paramount importance. OPN was involved 
in promoting tumourigenicity and malignant dissemination of 
breast cancer cells. The possibility of using OPN as a prognostic 
marker and a molecular target for therapeutic intervention in 
breast cancer cells has been well assessed (1-3). Similar to 
breast cancer, prostate cancer is also a hormone responsive 
cancer. Recently, over-expression of OPN in prostate cancer 
was reported and the prognostic significance of the increased 
OPN expression to prostate cancer patient survival has also 
been investigated (4). It is interesting to see whether the 
tumourigenicity of prostate cancer cells can be suppressed by 
inhibiting OPN expression as that observed in breast cancer. 
OPN was first discovered by Senger et al in 1979 as a 
phosphoprotein secreted by transformed, malignant epithelial 
cells (5). It was rediscovered 10 years later, using molecular 
cloning, as a transformation-associated phosphoprotein whose 
level of expression was correlated with tumourigenicity (6). 
OPN was expressed in multiple species, such as human and 
rodents and it was found in various tissues and cell types, even 
in biological fluids (7-14). Human OPN gene is located in 
chromosome 4q13 and consist of seven exons (15,16). OPN 
was suggested to inhibit apoptosis in cancer through activation 
of the phosphatidylinositol 3-kinase/Akt pathway, to suppress 
integrin-mediated cell death, to induce an NFκB mediated 
pathway (17-19). It was demonstrated that OPN induced 
invasion and metastasis by activating MMPs through several 
overlapping pathways (20-22). It was previously shown in 
this laboratory (4) that OPN was expressed in higher levels in 
both malignant prostate cancer cells and carcinoma tissues. 
The increased expression of OPN was significantly correlated 
with the reduced patient survival and both OPN staining 
intensity and Gleason scores have a similar prognostic 
significance. OPN was associated with CD44 and MMP9 in 
migration of prostate cancer cells (23). The OPN/integrin αvβ3 
signaling pathway was involved in the migration and invasion 
of PC3 cells via regulating the formation and function of 
invadopodia (24). All these studies suggested that OPN play 
an important role in the malignant progression of prostate 
cancer and thus it is worthwhile to investigate whether OPN 
might serve as a target for therapeutic intervention in prostate 
cancer.
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Materials and methods
Cell lines and culture condition. DU145 (25) cells were grown 
in monolayer culture in RPMI-1640 (PAA, Pasching, Austria) 
supplemented with 10% (v/v) fetal bovine serum (Biosera, 
UK), L-glutamine (20 mM), penicillin (100 U/ml) and 
streptomycin (100 U/ml), and maintained in a humidified 
incubator (model TC2323, Borolabs Ltd., UK) at 37˚C with 
5% (v/v) CO2. For transfected cells during and after the 
selection process, geneticin G418 (PAA Labs GmbH, Pasching, 
Austria) was added to the culture medium at a concentration 
of 1 mg/ml. 
siRNA sequences and expression constructs. Three unique 
21nt sequences (Table I) were selected respectively from 
OPN-cDNA using the siRNA target design tool on the website 
of the Biotech Company Ambion (www.ambion.com) and 
the uniqueness of the sequences were confirmed by BLAST 
for their high specificity. For transient transfection, a double 
stranded RNA targeting each 21nt sequence was designed and 
synthesized. For stable transfection, a short DNA molecule 
was commercially purchased as two separate oligos. These 
two complementary DNA oligos were annealed to form a 
double stranded siRNA insert and ligated into a pSilencer™ 
4.1-CMv neo vector (Ambion, UK) by HindIII and BamH1 
sites. The plasmid containing specific siRNA sequences 
were transformed respectively into DH5α competent E. Coli 
cells and the presence of the siRNA insert was confirmed by 
sequencing analysis using an internal sequence primer 
(5'-ATTAACCCTCAGTAAAGGGA-3'). Results were 
analysed using BIOEDIT sequence visualisation software. 
Transient and stable transfection. Transient transfection of 
the siRNAs into highly malignant DU145 cells was performed 
with a siPORT NeoFX transfection reagent (Ambion) following 
the manufacturer's instruction. The most efficient siRNA 
was determined by Western blotting performed to test the 
levels of OPN in cells after the different transient transfections. 
A siPORT XP-1 transfection agent kit (Ambio, UK) was used 
to perform the stable transfection following the manufacturer's 
instruction. Cells were plated at 2x105/dish in routine medium 
~24 h before the transfection, to reach 30-60% confluence. 
After the siPORT XP-1/DNA complex was overlaid dropwise 
onto the cells, the plate was transferred into a selection medium 
(normal medium containing 1 mg/ml G418) to select the 
clones harbouring plasmid DNA. Western blotting was used 
to detect the levels of OPN in transfectants. In a parallel, but 
separate transfection, a scrambled RNA was transfected to 
DU145 cells in the same way to generate a pool of control 
transfectants. 
Detection of protein expression in cultured cells. OPN protein 
expressed in cultured cells was detected by Western blotting, 
using an ECL detection system (26). Proteins were extracted 
and equal amounts of total protein from each cell lines were 
quantified with a Coomassie Protein Assay Reagent kit 
(Bio-Rad Laboratories GmbH, Munchen, Germany). Samples 
containing equal amounts of total protein were subjected to 
SDS-PAGE in 9% polyacrylamide gels together with molecular 
weight markers. Separated proteins were transferred onto a 
nitrocellulose membrane (Hybond-ECL, GE Healthcare, UK) at 
100 V for 2 h at 4˚C. The membrane was first incubated with 
pre-block reagent Protoblock (National Diagnostics, UK) for 
an hour at room temperature and then incubated with the 
MPIIIB10 ascites (OPN) (Developmental Studies Hybridoma 
Bank, USA) in 1:200 for OPN at 4˚C overnight. The membrane 
was then incubated with polyclonal rabbit anti-mouse immuno-
globulins/HRP (Dako, UK) at a dilution of 1:1000 for 2 h at 
room temperature. The bound antibodies were revealed by 
ECL Advance (GE Healthcare, UK) and recorded on Kodak 
XAR-5 film. The bands were scanned using Alpha-Imager 2000 
software (Alpha Innotech, Cannock, UK) and the intensity of 
band was obtained by measuring the peak area. The relative 
levels of OPN expression in different cell lines were obtained 
by comparing the intensity of bands. Blots were incubated 
with monoclonal anti-β-actin (Sigma) to correct the possible 
loading errors.
Soft agar colony-formation assay. Soft agar assay was performed 
to test the anchorage-independent growth of the cells as an 
indication of their tumourigenicity in vitro. In this study, 
parental cells and the siRNA transfected cells were cultured 
in soft agar to determine their ability to form colonies in an 
anchorage-independent environment. One percent of soft agar 
gel-I (SA-I) was made from 2% low melting temperature 
agarose (LMA) mixed with equal amount of routine medium 
for parental cells while 1% of soft agar gel-II (SA-II) was made 
from 2% LMA mixed with equal amount of routine medium 
with G418 for the scrambled-RNA control cells and siRNA-
transfected cells. SA-I and SA-II were plated at 1 ml per well 
in a 6-well plate and placed at 4˚C to solidify the basement 
gel layer. Parental cells, control cells, and OPN-suppressed 
transfectants were harvested separately, adjusted with SA-I or 
SA-II to 3x103 cells/ml, plated on top of the preset basement 
gel layer and placed at 4˚C for 10 min for solidification. Once 
set, the cells in plates were incubated at 37˚C in a humidified 
atmosphere of 5% CO2 for 8 weeks. All soft agar gels were 
stained with 2% MTT for 4 h. Plates were scanned and the 
colonies were counted using an Optronix Gel Count (Oxford 
Optronix, UK).
Proliferation assay. The control and transfectant cells were 
cultured in normal RPMI-1640 medium in 96-well plates in 
triplicates. Each single well contained 2,000 cells growing in 
200 µl of medium. The number of cells in one well from each 
plate was counted by the MTT colour metric method every 
24 h during the 6-day experiment period, as described before 
(27). 
Invasion and motility assay. Invasiveness of the control and 
different transfectant cells was measured by an invasion assay 
(28) with some modifications (29). All cell lines were set as 
triplicate and the assay run for 24 h in the incubator at 37˚C. 
Invaded cells on the lower side of the filter were fixed and 
stained with Crystal violet and the number of the stained 
cells on the lower side of the chamber was counted under a 
microscope. For motility assay, culture medium, experimental 
condition and analytic method were similar to those used in 
the invasion assay except no matrigel was used and test cells 
were adjusted to 4x105 cells/ml. 
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Nude mouse assay. To test the tumourigenicity in vivo, the 
transfectant cells were inoculated in BALB/c male nude mice 
to produce tumours, as described previously (30). Six to eight 
week-old male BALB/c nude mice (purchased from Charles 
River Laboratories, UK) with body weights ranged from 
18-20 g on arrival, were used to inoculate the transfectants. 
For each mouse, a subcutaneous injection of 200 µl suspension 
(PBS:Matrigel=1:1) containing 2x106 cells from different cell 
lines was given on the right shoulder region. Body weight and 
the tumour size were measured twice a week using a calliper. 
Tumour volume was calculated by the formula 0.5236 x (length) 
x (width) x (height) (31). The animals were maintained for 
4 weeks, or until the tumours reached 17 mm in one dimension 
before they were sacrificed. All animal work was conducted 
in accordance to UKCCCR guidelines under Home Office 
project licence PPL40/2270 to Professor Y. Ke.
Detection of OPN expression in tumour tissues by Western 
blot analysis and immunohistochemistry. At autopsy, some 
parts of tumours were frozen in liquid nitrogen and some 
were fixed in 10% formalin. Upon starting the analysis, the 
frozen tumour samples were defrosted on ice and tissues were 
cut into small pieces. Total protein was extracted with CelLytic 
M Cell Lysis reagent (Sigma, USA). Tissues were sonicated 
and centrifuged at 13,000 rpm for 30 min. The supernatant 
containing the protein was transferred to a new microfuge tube to 
make cell extracts which were subjected to Western blot analysis 
to measure the levels of OPN expression. Fixed tissues in 10% 
formalin were trimmed, embedded in paraffine wax, cut into 
4 µm sections and mounted onto APES slides using standard 
routine procedure (26). Tissue sections were stained immuno-
histochemically to detect OPN expression. The procedure for 
tissue staining was similar to those described previously (4,26). 
Sections were dewaxed in xylene rehydrated in Industrial 
Methylated Spirits (IMS) (GENTA Environmental Ltd., UK) 
before being transferred into fresh H2O2/methanol for 12 min to 
block endogenous peroxidase activity. Sections were incubated 
with the primary antibody, MPIIIB10 ascites (Developmental 
Studies Hybridoma Bank), at 1:250. Bound antibody was 
detected with 100 µl of labelled polymer (DakoCytomation, 
UK) and visualised with DAB (DakoCytomation) for 10 min. 
After briefly counterstained with hematoxylin solution, sections 
were mounted in DPX (Bios, UK).
Statistical analysis. Statistical analyses were performed using 
the PASW package, version 17.0 (SPSS Inc., USA). Data from 
the soft agar assay, proliferation assay, invasion and motility 
assay were assessed using Student's t-test. Differences on sizes 
of tumours produced in mice were also assessed by Student's 
t-test. Correlations between tumour volumes and OPN levels 
were assessed by Box plot and Mann-Whitney U test. p<0.05 
was defined as statistically significant.
Results
Selection of the most efficient siRNA for OPN suppression. 
Three 21-nt sequences within the OPN cDNA were selected 
as tagets for siRNA (Table I). Three siRNAs based on these 
sequences were synthesized and transiently transfected into 
the highly malignant DU145 prostate cancer cells either singly 
or in different combinations. After 72 h, Western blot analysis 
was performed to quantify OPN expression levels in differently 
transfected cells (Fig. 1). SiRNA-1 exhibited the highest 
efficiency in OPN suppression by producing a nearly 80% 
reduction in the level of OPN detected in the control DU145 
cells. Thus, siRNA-1 was identified as the most efficient OPN 
suppressor and the sense and antisense sequences (Table I) 
which form a template for siRNA-1 transcript were synthesed 
for stable transfection. 
Suppression of OPN expression in DU145 cells by RNA 
interference. The sense and antisense oligonucleotides based 
on siRNA-1 sequence were annealed to form a double stranded 
siRNA insert and ligated into a pSilencer 4.1-CMv neo vector 
(Ambion) to form a construct capable of expressing siRNA-1; 
and this construct was stably tranfected in DU145 cells as 
described in Materials and methods. A scambled RNA was also 
transfected in parallel to generate a pool of control transfectants. 
Three months after the initial transfection, 5 clones from 
siRNA-1 construct transfectants were established. The rest of 
the transfectants were pooled together. The levels of OPN 
expressed in the transfectant pool, control cells and in each of 
Table I. The details of OPN target sequences and their siRNAs.
Sequence-1: 5'-AAATTCTGGGAGGGCTTGGTT-3'  Sense: 5'-GATCCATTCTGGGAGGGCTTGGTTTTCAA
   GAGAAACCAAGCCCTCCCAGAATTTA-3' 
   (AUUCUGGGAGGGCUUGGUUUU) 
  Antisense: 5'-AGCTTAAATTCTGGGAGGGCTTGGTTTCT 
   CTTGAAAACCAAGCCCTCCCAGAATG-3'
   (AACCAAGCCCUCCCAGAAUUU)
Sequence-2:  5'-AAGTCCAACGAAAGCCATGAC-3' Sense:  (GUCCAACGAAAGCCAUGACUU) 
  Antisense:  (GUCAUGGCUUUCGUUGGACUU) 
Sequence-3: 5'-AAGATATGCTGGTTGTAGACC-3'  Sense: (GAUAUGCUGGUUGUAGACCUU) 
  Antisense:  (GGUCUACAACCAGCAUAUCUU)
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the 5 clones were measured by Western blot analysis and the 
results were shown in Fig. 2. When the OPN level expressed 
in the control cells was set at 1, the level of OPN in the 
transfectant pool was sharply reduced by 6.3 times to 0.16. 
For the 5 cell lines derived from separate clones, there was a 
clone which did not exhibit any OPN reduction (lane 3), instead, 
its OPN level was 1.23 times of that detected in the control. 
The OPN expression was suppressed in all other 4 clones, 
with levels varied from an almost complete suppression (lane 7) 
to a 12% reduction (lane 6). Two clones (lanes 4 and 7) which 
exhibited the greatest OPN suppression were identified and 
named C1 and C2, respectively.
Effect of suppression of OPN on DU145 cells in vitro. The 
effect of OPN suppression on characteristics of DU145 cells 
was tested by several assays. The anchorage-independent growth 
of the cells was assessed by a soft agar assay and the result 
was shown in Fig. 3A. While no significant difference (Student's 
t-test, p=0.14) was observed between the number of colonies 
formed by the parental DU145 cells and the control cells, the 
numbers of colonies produced by OPN-highly-suppressed 
cells C1 (Student's t-test, p<0.0001) and C2 (Student's t-test, 
p<0.001) were significantly reduced by 61.5 and 92.7%, 
respectively, in comparison with that developed from the control 
cells. 
Cell proliferation assay was performed to measure the 
growth rate of the parental DU145 cells, the control, C1 and 
C2 cells, and the result was shown in Fig. 3B. When compared 
with the control, no differentce was detected on numbers of 
the control cells at any of the time-points. Although some 
reductions on numbers of C1 and C2 cells were detected at all 
time points after the first measurement, these differences were 
not significant (not shown). Thus OPN suppression did not 
significantly change the cell proliferation rate. 
The invasiveness of different cells was assessed using an 
invasion assay as described in Materials and methods. While 
no significant (Student's t-test, p=0.75) difference between 
parental DU145 and the control cells was observed, the 
invasiveness of C1 (Student's t-test, p<0.0001) and C2 (Student's 
t-test, p<0.0001) were significantly reduced by 92.9 and 88.3% 
respectively, in comparison with the control (Fig. 3C). Thus 
suppression of OPN expression significantly reduced the 
invasiveness of the cells. 
The motility of the cells was tested by acrossing transwell 
polycarbonate membranes as described in Materials and 
methods. No significant (Student's t-test, p=0.62) difference 
was observed between parental DU145 and the control cells. 
The motility of C1 (Student's t-test, p=0.18) and C2 (Student's 
Figure 1. Levels of OPN expressed in DU145 cells transfected transiently 
with different siRNAs. (A) Western blot analysis of OPN expression in 
DU145 cells transfected transiently with different siRNAs: lane 1, siRNA-1; 
lane 2, siRNA-2; lane 3, siRNA-3; lane 4, siRNA-1+2; lane 5, siRNA-1+3; 
lane 6, siRNA-2+3; lane 7, siRNA-1+2+3; lane 8, reagents only (control). 
(B) Relative OPN levels expressed in DU145 cells after different transient 
transfections. Relative OPN levels were measured by densitometry analysis 
of the bands on the blots. The OPN level in control cells was set as 1.0. The 
levels of OPN in other lanes of the blot were calculated by relating to the 
control cells. The possible loading errors were corrected by relating to the 
amount of β-actin. Results were obtained from three separate measurements 
(mean ± SE). 
Figure 2. Levels of OPN expression in different stable transfectant cells. 
(A) Western blot analysis of OPN expression in scrambled RNA transfectants 
(control) and in different clones derived from siRNA-1 stable transfectants: 
lane 1, control; lane 2, pool of siRNA-1 transfectants; lanes 3-7, different 
individual colonies separated from siRNA-1 transfectants. The antibody 
against β-actin was used to standardise the loading amongst different wells 
of the blot. (B) Relative OPN levels in control, tansfectants pool and each of 
the different colonies. The OPN levels were obtained by densitometry 
analysis of the bands on the blot. The level in control cells was set at 1.0 
and levels of OPN expressed in the siRNA-1 tansfectants pool and each of 
the different colonies were calculated by relating to that in the control. The 
possible loading errors were corrected by relating to the bands of β-actin. 
Results were obtained from three separate measurements (mean ± SE).
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t-test, p=0.72) were not significantly different in comparison 
with the control (Fig. 3D). Thus, suppression of OPN expression 
had no significant effect on cell motility.
Effect of suppression of OPN on tumourigenicity in vivo. To 
assess the effect of the suppression of OPN on tumourigenicity, 
the control, C1 and C2 cells were inoculated respectively into 
3 groups (10 mice per group) of male balb/c nude mice. All 3 
cell lines produced tumours respectively in all 30 nude mice 
(100% tumour incidence). Tumours appeared in either the 5th 
or the 6th day in all experimental mice after the inoculation 
and no difference was observed in the average lengths of the 
letant periods amongst the 3 different groups (data not shown). 
The average tumour sizes amongst the 3 groups of mice did 
not exhibit any remarkable differences until the 5th round 
of measurements at day 13 when the tumours of the control 
group started to grow faster than those of the C2 group which 
grew faster than C1 group. This growing pattern remained 
until the end of the experiments (Fig. 4A). On the 23rd day 
post-inoculation, the average volumes of tumours produced by 
the control, C1 and C2 were 347.9±38.8, 102.2±26.5, and 
204.9±53.6 mm3 respectively (Fig. 4B). In comparison with 
the average sizes, the average volumes of tumours in C1 and 
C2 groups were significantly reduced by 70.1% (Student's 
t-test, p<0.001) and 41.1% (Student's t-test, p<0.01), respectively. 
Between the two OPN-suppressed groups, the tumours produced 
by C2 group were significantly (Student's t-test, p<0.05) larger 
(2 times) than those produced by C1 cells. A representative 
tumour-bearing mouse and the tumour developed inside it 
were taken from each group of mice and shown in Fig. 4C. 
Expression of OPN in mouse tumours. Total protein extracts, 
prepared from each of the tumours produced in 3 groups of 
mice were subjected to Western blot analysis to detect the 
OPN expression. The results were summuried in Fig. 5A. 
When the average level of OPN in the tumours of the control 
group was set at 1, the relative levels of OPN expressed in C1 
and C2 groups were 0.4±0.12 and 0.53±0.09, respectively. 
Therefore, in comparison with the control group, the levels of 
OPN in C1 and C2 groups were reduced by 60 and 47%, 
respectively. Interestingly, the OPN level detected in tumours 
produced by C2 group was 32.5% higher than that detected in 
tumours produced by C1 groups. Immunohistochemical 
stains of tumour tissues with OPN antibody (Fig. 5B) showed 
that strongest staining was observed in the control group 
and moderate staining was observed in C2 tumours. The 
weakest stain was observed in C1 tumours. Thus the patterns 
of immunohistochemical stains were similar to those measured 
by Western blot analysis.
Correlations between levels of OPN expression and volumes 
of tumours. Tumours developed from all 30 mice were divided 
to three groups according to their relative OPN levels, irrespective 
of their cell origins: low (<0.4), moderate (0.4-0.75) and high 
Figure 3. The effect of suppressing OPN expression on cell characteristics. (A) Numbers of colonies produced in soft agar by the parental DU145 cells (1), the 
control (2), C1 (3) and C2 cells (4). Results were obtained from three separate assays (mean ± SE). (B) Proliferation rates of the parental DU145 cells, the 
control, C1 and C2 on different time-points. Results were obtained from three separate assays (mean ± SE). (C) Numbers of invaded cells from different cell 
lines: 1, DU145; 2, control transfectants; 3, C1; 4, C2. The results were obtained from 3 separate assays (mean ± SE). (D) Numbers of motile cells from 
different cell lines: 1, DU145; 2, control transfectants; 3, C1; 4, C2. The results were obtained from 3 separate assays (mean ± SE).
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(>0.75) (the level in the highest OPN tumour was set at 1). For 
tumours expressing low, moderate and high levels of OPN, the 
median tumour volumes were 68.1±15.5, 146.6±65.1 and 
381.2±120.3 mm3, respectively. The correlation between the 
levels of OPN expression and the tumour volumes is assessed 
by Box plot analysis and the results are shown in Fig. 6. Box 
plot analysis showed that the volumes of the tumours with 
high OPN expression levels were significantly higher than 
those with moderate (Mann-Whitney U test, p=0.0001) and 
Figure 4. Tumours produced by different cells in nude mice. (A) Average 
sizes of tumours (measured at different time-points) developed in 3 groups of 
mice inoculated with the control, C1 and C2 cells, respectively. (B) Average 
volumes of tumours produced in each of the 3 groups of mice at autopsy on 
day 23. (C) One representative tumour-bearing mouse taken from each of the 
3 groups of mice inoculated with the control (a), C1 (b), and C2 (c) cells 
respectively. The tumour of each mouse is shown in the insert. 
Figure 5. OPN expression in tumours produced in different groups of 
animals. (A) Relative OPN levels in tumours developed in different groups 
of mice by Western blot analysis. The average level of OPN in control group 
was set at 1.0. The average OPN levels detected in other groups were calculated 
by relating to that expressed in the control group. The possible loading errors 
were corrected by relating to the amount of β-actin. (B) Immunohistochemical 
staining of OPN expressed in tumour tissues taken from different groups of 
mice. (a) control, (b) C1, (c) C2, (d) positive (left) and negative (right) staining 
controls. Magnification x100.
Figure 6. Correlations between levels of OPN expression and volumes of 
tumours. Acording to their OPN levels, tumours from each of entire 
experimental mice were divided into 3 groups: group 1 or low OPN level 
group (n=12); group 2 or moderate OPN level group (n=11), and group 3 or 
high OPN level group (n=7). Correlations between levels of OPN and 
volumes of tumours were assessed by comparing the average OPN levels 
with the average tumour volumes in each of the 3 groups with Mann-
Whitney U test. 0, representative of outlier values; and *representative of 
extreme values.
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low (Mann-Whitney U test, p=0.001) OPN expression level. 
Tumours with moderate OPN expression levels were also 
significantly (Mann-Whitney U test, p=0.015) larger than 
those with low OPN expression level.
Discussion
OPN was shown to be highly expressed in a variety of cancers, 
particularly breast cancer which is a hormone responsive cancer 
like prostate cancer (32). Recent studies demonstrated the 
potential of using OPN as a prognostic marker and therapeutic 
target for breast cancer (33-36). In contrast to the well-established 
important role of OPN played in development and metastasis 
of breast cancer, the involvement of OPN in prostate cancer 
was not established until recently. Although some initial reports 
suggested that OPN might be overexpressed in human prostate 
cancer cells (37,38), its biological significance was disputed 
(39). To clarify the discrepancies reported in the early studies, 
we investigated the OPN expression status in an archival set 
of a large number of benign and malignant prostate tissues 
and firmly established that the increased expression was 
significantly associated with the degree of malignancy of 
prostate cancer and that the level of OPN expression is an 
important determinant for patient survival (4).
In this work, we investigated the possible role of OPN in 
tumourigenicity of prostate cancer by suppressing OPN 
expression in the highly malignant prostate cancer cell line 
DU145 and succesffuly established several clones, in which 
different degree of suppression in OPN expression was achieved 
by RNAi technique. While bioassay in vitro results showed 
that OPN suppression did not significantly change the cell 
proliferation rate and cell motility, it did have great effect on 
tumourigenicity and invasiveness. The invasion assay results 
showed that comparing with the control, the invasiveness of 
C1 and C2 cells were significantly reduced by 92.9 and 88.3%, 
respectively (Fig. 3C). Thus suppression of OPN expression 
significantly reduced the invasiveness of the cells. The soft 
agar assay results showed that comparing with the control, the 
number of colonies produced by OPN-moderately-suppressed 
cells C1 and OPN-highly-suppressed cells C2 were signifi-
cantly reduced by 61.5 and 92.7%, respectively (Fig. 3A). 
Thus the reduced tumourigenicity in vitro was associated with 
the decreasing level of OPN in a propotional manner. These 
results suggested that OPN may be a promoting factor in 
prostate cancer cells and it may play a promoting role by 
facilitating tumourigenicity and invasiveness of the cancer 
cells. These results are consistent with previously reported 
role of OPN in other types of cancers (32). 
The effect of the reduced expression of OPN on the ability 
of the cancer cells to form tumours in vivo was assessed by 
nude mouse assay. At the end-point of the experiments, the 
average volume of tumours produced by the control, C1 and 
C2 cells was 347.9±38.8, 102.2±26.5, and 204.9±53.6 mm3, 
respectively (Fig. 4B). Thus, in comparison with the control, 
the average volumes of tumours in C1 and C2 groups were 
significantly reduced by 70.1% (Student's t-test, p<0.001) and 
41.1% (Student's t-test, p<0.01), respectively. These results 
showed that suppressed OPN expression significantly inhibited 
the tumourigenicity of the DU145 cells in vivo. However, this 
inhibition in tumour growth was not quantitatively related to 
the degree of OPN level reduction measured in the transfectants 
before the inoculation. As showed in the results, the average 
size of tumours produced by C2 cells (204.9±53.6 mm3), which 
hardly express any OPN, was twice as big as that produced by 
C1 cells which expressed 12% of the level of OPN measured 
in the control cells (Fig. 2). Thus, this result seemed not to be 
quite consistent with that observed in the soft agar assay in vitro. 
To find out the possible reason for this difference, we 
investigated the expression status of OPN in the tissues of the 
tumours developed in nude mice. It was found that the 
patterns of OPN expression amongst the 3 groups of tumours 
were not the same as those measured in the transfectnats 
before the inoculation. When the average level of OPN in the 
tumours of the control group was set at 1, the relative levels 
of OPN expressed in C1 and C2 groups were 0.4±0.12 and 
0.53±0.09, respectively (Fig. 5). In comparison with the 
control group, the level of OPN in tumours produced by C1 
and C2 groups was reduced by 60 and 47%, respectively. Thus 
the level of OPN detected in C2 tumours was actually 32.5% 
higher than that detected in C1 tumours. Immunohistochemical 
staining of tumour tissues with OPN antibody exhibited a 
similar results, further supported the OPN expression pattern 
detected by Western blotting. To study further the correlations 
between levels of OPN expression and volumes of tumours, 
we measure OPN levels in all tumours developed from the 
entire 30 mice and divided them into three groups according 
to their relative OPN levels, irrespective of their cell origin. 
For tumours expressing low, moderate and high level of OPN, 
the median tumour volumes were 68.1±15.5, 146.6±65.1 and 
381.2±120.3 mm3, respectively. Box plot analysis showed that 
the volumes of the tumours with high OPN expression level 
were significantly higher than those with moderate or low 
OPN expression level. Tumours with moderate OPN 
expression level were also significantly larger than those with 
low OPN expression level (Fig. 6). These results taken together 
suggested that suppression of OPN expression can inhibit 
tumour growth in a quantitatively-related manner. Reduction 
of tumour sizes in this batch of experimental mice is 
propotionally associated with the decreasing level of OPN 
expression. Thus OPN is a determinant factor of the 
tumourigenicity in prostate cancer cells. 
An interesting observation is the difference in OPN 
expression levels between the transfectants in vitro and tumours 
produced by the same transfectants in nude mice. For example, 
the OPN level in C2 cells was hardly detectable, but this was 
increased remarkably in the tumour produced by these cells 
in vivo, indicating that the RNAi suppression functions were 
partially lost or a desuppression process might have occurred 
during the inoculation in nude mice. The mechanism for this 
is not understood currently. Although RNAi is a technique 
widely used to suppress the expression of specific genes in a 
variety of studies (40-42) on different fields of molecular 
biology, the exact mechanisms on many aspects are not fully 
understood. Controversial results were reported by several 
laboratories (43-45). It was reported that several dsRNAs 
induce gene transcription in a sequence-specific manner by 
targeting the promoter region of various genes (44). This 
RNAi was also named RNA activation or ‘RNAa’, and these 
siRNAs were identified leading to the activation and increased 
levels of some genes in human cells (46). The difference in 
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OPN level of the transfectants between the in vitro and in vivo 
environments may be a reflection of the complicated mechanisms, 
through which the RNAi molecules interact with their targeting 
genes in different surrounding conditions. 
In conclusion, increased expression of OPN may play an 
important role in development and expansion of prostate 
cancer and the changes in OPN level have a determinant effect 
on the sizes of tumours. Thus OPN should be a reliable target 
for therapeutic intervention providing an efficient and stable 
method is used to inhibit the expression of OPN in the cancer 
cells. 
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